Mountain View, California, United States - HeartFlow, Inc., a provider of precision heart care, raises $215 million in a Series F funding round led by Bain Capital Life Sciences, with participation from new investor Janus Henderson Investors and existing investors including Baillie Gifford, Capricorn Investment Group, Hayfin Capital Management, HealthCor, Martis Capital, USVP, and Wellington Management.

HeartFlow is a medical technology company that is revolutionizing the diagnosis and treatment of cardiovascular disease. Physicians can make better care decisions for their patients with suspected coronary artery disease, the world's leading killer of men and women, using the HeartFlow Analysis, a non-invasive personalized cardiac test. HeartFlow is backed by decades of scientific research and development, and it leverages the most recent technological advancements to help set a new standard of care for diagnosing cardiovascular disease around the world.

According to John Farquhar, the founder, and CEO of HeartFlow, the new funding will allow the company to meet the growing demand for its commercial products, support a robust body of growing clinical evidence, and advance its comprehensive product portfolio to assist physicians in diagnosing coronary artery disease (CAD) and guiding their treatment decisions.